What's New - International Drug Detection

 

What's New (continued)

On Site Testing now available!

The International Drug Detection team is taking its high standard of drug and alcohol testing on the road with its new state-of-the-art mobile testing vehicle. This huge freightliner, which is 39 feet long, contains four complete collection stations, two bathrooms and reception area along with satellite communication. With this latest addition to the IDD fleet, technicians can now provide testing that adheres to strict Federal regulations at remote sites that previously were not possible to conduct.

The new mobile testing facility, which is nicknamed "The Bus", is an example of how IDD combines old-fashion work ethics with new technology while complying with constantly changing rules and regulations.

DOT PART 40 UPDATE

Direct Observation in Effect for All DOT Return-to-Duty and Follow-Up Drug Testing (§ 40.67)

When and how is a directly observed collection conducted?
(b) As an employer, you must direct a collection under direct observation of an employee if the drug test is a return-to-duty test or a follow-up test.

(i) As the observer, you must request the employee to raise his or her shirt, blouse, or dress/skirt, as appropriate, above the waist; and lower clothing and underpants to show you, by turning around, that they do not have a prosthetic device. After you have determined that the employee does not have such a device, you may permit the employee to return clothing to its proper position for observed urination.

DOT Interim Final Rule - Effective October 1, 2010


Posted for display in Federal Register for publication on Monday September 27, 2010 is a Department of Transportation Interim Final Rule: Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Federal Drug Testing Custody and Control Form; Technical Amendment

The IFR provides instructions to employers, collectors, laboratories, and Medical Review Officers (MROs) for use of the new Department of Health and Human Services (HHS) Federal Drug Testing Custody and Control Form (CCF), and it offers a technical amendment to laboratories regarding mandatory reporting of confirmed positive drug / drug metabolite quantitations to MROs.

Regarding Use of the CCF:
1. DOT- regulated employers and their service agents are authorized to begin using the new CCF on October 1, 2010.

2. The IFR provides instructions for:

a. Filling out Step 1-D on Copy 1 of the new CCF, which now includes the Federal testing authorities - HHS; DOT; and Nuclear Regulatory Commission (NRC), with further specificity for the DOT Agencies – FMCSA; FAA; FRA; FTA; PHMSA; and the USCG;

b. Filling out Step 5-A on Copy 1 of the new CCF, which now lists MDMA, MDA, and MDEA, as well as "9-THCA" after "Marijuana Metabolite" and "BZE" after "Cocaine Metabolite" to specify the drug analytes;

c. Filling out Step 6 on Copy 2 of the new CCF, which now has a line for the MRO to note the drug(s) for which a positive result is verified, and a new line item "other" for documenting other "refusal to test" situations - for example, when there is no legitimate medical explanation for the employee providing an insufficient amount of urine;

d. Filling out Step 7 on Copy 2 of the new CCF, which now has a box the MRO is to check if a split specimen is reported as cancelled; and e. Revised instructions for completing the CCF are on the reverse side of Copy 5.
3. Use of old CCFs is permitted through September 30, 2011, because of the large number of existing supplies. If the old CCF is used on or before September 30, 2011, collectors and laboratories will:

a. Collector: Write in the specific DOT Agency under which the specimen is collected in the Remarks Section in Step 2 on Copy 1 of the old CCF.

b. Laboratory: Before transmitting a confirmed positive drug test for MDMA, MDA, or MDEA, as appropriate, to the MRO, check "positive" box and write in the specific MDMA, MDA, or MDEA analyte in the "Remarks" section in Step 5-A of Copy 1.
Other Items:
• In harmonizing with HHS, Part 40 will require mandatory reporting of confirmed positive drug/drug metabolite quantitations by laboratories to MROs.
• A new section §40.14 was added to spell-out, in one place, the information employers and their C/TPAs must routinely provide to collectors.





FEATURED SERVICES

 

Federal DOT mandates that only the following five drugs be tested for: amphetamines, cocaine, cannabinoids, opiates, and phencyclidine. Additional drugs beyond these five are considered non-DOT drug panels and must be tested separately. For clients that are not federally mandated they can choose what drugs they want for the testing panel and how many.